GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Schedule 1 - Original Invest

6 Oct 2006 16:28

AIM06 October 2006 ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH AIM RULE 2 ALL APPLICANTS MUST COMPLETE THE FOLLOWING: COMPANY NAME: ORIGINAL INVESTMENTS PLC (TO BE RENAMED VIALOGY PLC ON ADMISSION) COMPANY ADDRESS: ASHCOME COURTWOOLSACK WAYGODALMINGSURREY COMPANY POSTCODE: GU7 1LQ COUNTRY OF INCORPORATION: UK COMPANY BUSINESS OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTMENT STRATEGY TO BE DISCLOSED INACCORDANCE WITH SCHEDULE 2, PARAGRAPH (J) OF THE AIM RULES: ViaLogy was founded in 1999 by a group of senior scientists and managers in supercomputing and ultra-computingtechnologies at the Caltech/NASA Jet Propulsion Laboratory (JPL) in Pasadena, California. Leveraging their priorexpertise and work at JPL in remote sensing and signal processing, ViaLogy scientists developed a technology toseparate the background 'noise' that envelops weak signals called Quantum Resonance Interferometry (QRI), which has thepotential to be adapted to a wide range of measurement, instrumentation and other applications. The initial test results on QRI, undertaken in the microarray industry, indicated that the technology was able todetect and discriminate signals with an intensity 1,000 times lower than RMS (root mean square) background noise. Thetechnology was the subject of further development work undertaken in the mass spectrometry industry. Other developmentactivities were carried out in the areas of sensor data processing and transference. The board and management team of ViaLogy consider that the technology is sufficiently advanced to be of considerablebenefit in a number of industrial areas and a planned programme of commercialisation has commenced. Discussions at bothdevelopment and commercial levels are being held with a number of international companies and national authorities toverify the suitability of incorporating the ViaLogy technology into existing and/or new products. DETAILS OF SECURITIES TO BE ADMITTED (i.e. where known, number of shares, nominal value and issue price to which itseeks admission and the number and type to be held as treasury shares): 403,256,437 ORDINARY SHARES OF 1P EACH CAPITAL TO BE RAISED ON ADMISSION: NIL FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS: DIRECTORS: JAMES DERRICK SLATER, CHAIRMAN (TO RESIGN ON ADMISSION) TERENCE BOND, MANAGING DIRECTOR AND DEPUTY CHAIRMAN (TO BECOME EXECUTIVE CHAIRMAN ON ADMISSION) DR RICHARD PETER DIXEY, NON EXECUTIVE DIRECTOR (TO RESIGN ON ADMISSION) JULIAN GEORGE VIGGARS, NON EXECUTIVE DIRECTOR (TO RESIGN ON ADMISSION) PROPOSED DIRECTORS: MICHAEL WOODS KELLY, PROPOSED CHIEF EXECUTIVE OFFICER DR. SANDEEP GULATI, PROPOSED CHIEF TECHNICAL OFFICER GEORGE REHM, PROPOSED NON-EXECUTIVE DIRECTOR DR. ROBERT WILLIAM DEAN, PROPOSED NON-EXECUTIVE DIRECTOR PERSON(S) INTERESTED IN 3% OR MORE OF THE ISSUER'S CAPITAL, EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITALBEFORE AND AFTER ADMISSION: Existing Following AdmissionDirector Number of Percentage of Number of Percentage of Ordinary Shares issued ordinary Ordinary Shares issued ordinary share capital (%) share capital (%) James Derrick Slater 26,485,000 8.5 26,485,000 6.6Terence Bond 13,925,000 4.5 13,925,000 3.5Christopher Slater 12,585,000 4.0 12,585,000 3.1Atlas Capital S.A. 17,700,000 5.7 17,700,000 4.4Dr. John Broome 12,500,000 5.3 13,316,542 3.3Aeris Holdings AG Nil Nil 60,883,923 15.1 NAMES AND ADDRESSES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES: NONE ANTICIPATED ACCOUNTING REFERENCE DATE: 31 MARCH EXPECTED ADMISSION DATE: 30 OCTOBER 2006 NAME AND ADDRESS OF NOMINATED ADVISER: SEYMOUR PIERCE LIMITEDBUCKLERSBURY HOUSE3 QUEEN VICTORIA STREETLONDON EC4N 8EL NAME AND ADDRESS OF BROKER: SEYMOUR PIERCE LIMITEDBUCKLERSBURY HOUSE3 QUEEN VICTORIA STREETLONDON EC4N 8EL DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A STATEMENT THAT THISWILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES: SEYMOUR PIERCE LIMITEDBUCKLERSBURY HOUSE3 QUEEN VICTORIA STREETLONDON EC4N 8EL THE ADMISSION DOCUMENT CONTAINS FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES. DATE OF NOTIFICATION: 6 OCTOBER 2006 NEW/ UPDATE (see note): NEW This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
6th Apr 20204:40 pmRNSSecond Price Monitoring Extn
6th Apr 20204:36 pmRNSPrice Monitoring Extension
27th Mar 20203:00 pmRNSIssue of Share Options
25th Mar 20207:00 amRNSContract manufacturing agreement for COVID-19 test
16th Mar 20204:41 pmRNSSecond Price Monitoring Extn
16th Mar 20204:36 pmRNSPrice Monitoring Extension
13th Mar 202011:51 amRNSHolding(s) in Company
10th Mar 20207:00 amRNSAcquisition of French distribution channel
17th Feb 20207:00 amRNSCE Marking Technical File submission
14th Feb 202011:00 amRNSMedilink Award win for Outstanding Achievement
14th Feb 20207:00 amRNSTGA approves DPYD for sale in Australia
5th Dec 201912:10 pmRNSThe Healthcare+ Expo Taiwan
2nd Dec 20197:00 amRNSHalf-year Report
29th Nov 201912:05 pmRNSBionow Double Award Win
28th Nov 20197:00 amRNSOpening of New Facilities and Corporate HQ
15th Nov 20197:00 amRNSPrivate Investor Presentation
12th Nov 201910:12 amRNSNotice of Results
6th Nov 20191:52 pmRNSCapital Markets Day
1st Nov 20197:00 amRNSDirector/PDMR Shareholding
31st Oct 20197:00 amRNSLaunch of Yourgene FlexT Analysis Software
30th Oct 20197:00 amRNSIssue of Share Options
15th Oct 20197:00 amRNSAmerican Society of Human Genetics Annual Meeting
14th Oct 20197:00 amRNSHalf year trading update
1st Oct 20197:00 amRNSPrivate Investor Presentation
26th Sep 20197:00 amRNSCE-IVD Certification renewal
18th Sep 20197:00 amRNSLaunch of DPYD chemotoxicity diagnostic assay
17th Sep 20195:50 pmRNSResult of AGM
17th Sep 20197:00 amRNSAGM Statement
20th Aug 20197:00 amRNSNotice of AGM
19th Aug 201910:35 amRNSChange of Registered Office
16th Aug 20193:49 pmRNSHolding(s) in Company
16th Aug 20199:06 amRNSDirectorate Change
12th Aug 20197:00 amRNSAmendment to Share Options
1st Aug 20197:00 amRNSDirector/PDMR Shareholding
29th Jul 20197:00 amRNSAppointment of Director
10th Jul 20197:00 amRNSFinal Results, Business Update and Director Change
27th Jun 20197:00 amRNSNotice of Results
24th Jun 20197:00 amRNSYourgene participates in key global conferences
3rd Jun 20197:01 amRNSDirector's dealing
3rd Jun 20197:00 amRNSIssue of Share Options
9th May 20194:07 pmRNSDirector's dealing
9th May 20197:00 amRNSDirectors' dealing & warrant extension
1st May 20198:05 amRNSTotal Voting Rights
26th Apr 20195:12 pmRNSHolding(s) in Company
26th Apr 20195:01 pmRNSHolding(s) in Company
25th Apr 20194:40 pmRNSCompletion of Acquisition
18th Apr 20197:00 amRNSResults of Placing and Subscription
17th Apr 20194:50 pmRNSAppointment of Sole Corporate Broker
17th Apr 20194:48 pmRNSProposed Acquisition, Placing & Subscription
8th Apr 20197:00 amRNSFull-year Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.